Stocktube video
30/03/2012

Alliance Pharma CEO looks forward to continued good growth prospects

View full size
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: APH
Latest Price: 28.75p  (0,00%)
52-week High: 37.13p
52-week Low: 26.25p
Market Cap: 69.17M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Alliance Pharma
www.alliancepharma.co.uk

Alliance Pharma plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development, marketing and distribution of pharmaceutical products. Its brands include Nu-Seals, Forceval, Hydromol, Deltacortril, Symmetrel, Syntocinon, Naseptin, Syntometrine, Synacthen and Slow-K.

All RNS Press Releases

RNS Release - Notification of Preliminary Results

2nd Feb 2012, 7:00 am
RNS Number : 6451W
Alliance Pharma PLC
02 February 2012
 



For immediate release

2 February 2012

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Notification of Preliminary Results

 

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will announce its preliminary results for the year ended 31 December 2011 on Thursday 22 March 2012.

 

A briefing for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan Communications, 107 Cheapside, London EC2V 6DN.

 

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0) 1249 466966

John Dawson, Chief Executive


Richard Wright, Finance Director


www.alliancepharma.co.uk


 

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court / Jessica Fontaine


 



Numis Securities Limited

+ 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Oliver Cardigan


Corporate Broking: David Poutney


 

Notes to editors:

 

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

 

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections.  Alliance's sales are mainly prescription driven.  Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

 

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORLLFSDFFILIIF

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.